OBJECTIVE: To estimate minimally important differences (MIDs) in scores for the modified Rodnan Skin Score (mRSS) and Health Assessment Questionnaire-Disability Index (HAQ-DI) in a clinical trial on diffuse systemic sclerosis (SSc). PARTICIPANTS AND METHODS: 134 people participated in a 2-year, double-blind, randomised clinical trial comparing efficacy of low-dose and high-dose D-penicillamine in diffuse SSc. At 6, 12, 18 and 24 months, the investigator was asked to rate the change in the patient's health since entering the study: markedly worsened, moderately worsened, slightly worsened, unchanged, slightly improved, moderately improved or markedly improved. Patients who were rated as slightly improved were defined as the minimally changed subgroup and compared with patients rated as moderately or markedly improved. RESULTS: The MID estimates for the mRSS improvement ranged from 3.2 to 5.3 (0.40-0.66 effect size) and for the HAQ-DI from 0.10 to 0.14 (0.15-0.21 effect size). Patients who were rated to improve more than slightly were found to improve by 6.9-14.2 (0.86-1.77 effect size) on the mRSS and 0.21-0.55 (0.32-0.83 effect size) on the HAQ-DI score. CONCLUSION: MID estimates are provided for improvement in the mRSS and HAQ-DI scores, which can help in interpreting clinical trials on patients with SSc and be used for sample size calculation for future clinical trials on diffuse SSc.
RCT Entities:
OBJECTIVE: To estimate minimally important differences (MIDs) in scores for the modified Rodnan Skin Score (mRSS) and Health Assessment Questionnaire-Disability Index (HAQ-DI) in a clinical trial on diffuse systemic sclerosis (SSc). PARTICIPANTS AND METHODS: 134 people participated in a 2-year, double-blind, randomised clinical trial comparing efficacy of low-dose and high-dose D-penicillamine in diffuse SSc. At 6, 12, 18 and 24 months, the investigator was asked to rate the change in the patient's health since entering the study: markedly worsened, moderately worsened, slightly worsened, unchanged, slightly improved, moderately improved or markedly improved. Patients who were rated as slightly improved were defined as the minimally changed subgroup and compared with patients rated as moderately or markedly improved. RESULTS: The MID estimates for the mRSS improvement ranged from 3.2 to 5.3 (0.40-0.66 effect size) and for the HAQ-DI from 0.10 to 0.14 (0.15-0.21 effect size). Patients who were rated to improve more than slightly were found to improve by 6.9-14.2 (0.86-1.77 effect size) on the mRSS and 0.21-0.55 (0.32-0.83 effect size) on the HAQ-DI score. CONCLUSION: MID estimates are provided for improvement in the mRSS and HAQ-DI scores, which can help in interpreting clinical trials on patients with SSc and be used for sample size calculation for future clinical trials on diffuse SSc.
Authors: P J Clements; W K Wong; E L Hurwitz; D E Furst; M Mayes; B White; F Wigley; M Weisman; W Barr; L Moreland; T A Medsger; V Steen; R Martin; D Collier; A Weinstein; E Lally; J Varga; S Weiner; B Andrews; M Abeles; J Seibold Journal: Arthritis Rheum Date: 1999-11
Authors: P J Clements; W K Wong; E L Hurwitz; D E Furst; M Mayes; B White; F Wigley; M Weisman; W Barr; L Moreland; T A Medsger; V Steen; R W Martin; D Collier; A Weinstein; E Lally; J Varga; S R Weiner; B Andrews; M Abeles; J R Seibold Journal: Arthritis Rheum Date: 2001-03
Authors: Peter A Merkel; Philip J Clements; John D Reveille; Maria E Suarez-Almazor; Gabriele Valentini; Daniel E Furst Journal: J Rheumatol Date: 2003-07 Impact factor: 4.666
Authors: Dinesh Khanna; Daniel E Furst; Weng Kee Wong; Joel Tsevat; Philip J Clements; Grace S Park; Arnold E Postlethwaite; Mansoor Ahmed; Shaari Ginsburg; Ron D Hays Journal: Qual Life Res Date: 2007-04-03 Impact factor: 4.147
Authors: D Khanna; D J Lovell; E Giannini; P J Clements; P A Merkel; J R Seibold; M Matucci-Cerinic; C P Denton; M D Mayes; V D Steen; J Varga; D E Furst Journal: Ann Rheum Dis Date: 2007-09-24 Impact factor: 19.103
Authors: Raymond S Douglas; Angelo Tsirbas; Mark Gordon; Diana Lee; Nicole Khadavi; Helene Chokron Garneau; Robert A Goldberg; Kenneth Cahill; Peter J Dolman; Victor Elner; Steve Feldon; Mark Lucarelli; Jimmy Uddin; Michael Kazim; Terry J Smith; Dinesh Khanna Journal: Arch Ophthalmol Date: 2009-09
Authors: Corrie L Poelman; Laura K Hummers; Fredrick M Wigley; Cynthia Anderson; Francesco Boin; Ami A Shah Journal: J Rheumatol Date: 2014-11-29 Impact factor: 4.666
Authors: Dinesh Khanna; James R Seibold; Athol Wells; Oliver Distler; Yannick Allanore; Chris Denton; Daniel E Furst Journal: Curr Rheumatol Rev Date: 2010-05-01
Authors: Dinesh Khanna; Daniel E Furst; Philip J Clements; Yannick Allanore; Murray Baron; Lazlo Czirjak; Oliver Distler; Ivan Foeldvari; Masataka Kuwana; Marco Matucci-Cerinic; Maureen Mayes; Thomas Medsger; Peter A Merkel; Janet E Pope; James R Seibold; Virginia Steen; Wendy Stevens; Christopher P Denton Journal: J Scleroderma Relat Disord Date: 2017 Jan-Apr
Authors: Monique Hinchcliff; Diana M Toledo; Jaclyn N Taroni; Tammara A Wood; Jennifer M Franks; Michael S Ball; Aileen Hoffmann; Sapna M Amin; Ainah U Tan; Kevin Tom; Yolanda Nesbeth; Jungwha Lee; Madeleine Ma; Kathleen Aren; Mary A Carns; Patricia A Pioli; Michael L Whitfield Journal: J Invest Dermatol Date: 2018-01-31 Impact factor: 8.551
Authors: Dinesh Khanna; Chi-Hong Tseng; Daniel E Furst; Philip J Clements; Robert Elashoff; Michael Roth; David Elashoff; Donald P Tashkin Journal: Rheumatology (Oxford) Date: 2009-09-23 Impact factor: 7.580
Authors: Tien-I Karleen Su; Dinesh Khanna; Daniel E Furst; Gabriel Danovitch; Christina Burger; Paul Maranian; Philip J Clements Journal: Arthritis Rheum Date: 2009-12